DK3491025T3 - Fcrn-antistoffer og anvendelsesmetoder heraf - Google Patents

Fcrn-antistoffer og anvendelsesmetoder heraf Download PDF

Info

Publication number: DK3491025T3
Authority: DK; Denmark
Prior art keywords: methods; fcrn antibodies; fcrn; antibodies
Prior art date: 2016-07-29

Application number

DK17835436.1T

Other languages

English (en)

Inventor

Leona E Ling

Sucharita Roy

Nathaniel Washburn

Marilyn Kehry

David J King

James Meador Iii

Anthony Manning

Jan Hillson

Original Assignee

Momenta Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-29

Filing date

2017-07-31

Publication date

2024-01-15

2017-07-31 Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc

2024-01-15 Application granted granted Critical

2024-01-15 Publication of DK3491025T3 publication Critical patent/DK3491025T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Virology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Transplantation (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
Emergency Medicine (AREA)

DK17835436.1T 2016-07-29 2017-07-31 Fcrn-antistoffer og anvendelsesmetoder heraf DK3491025T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662368803P	2016-07-29	2016-07-29
US201662368770P	2016-07-29	2016-07-29
PCT/US2017/044765 WO2018023136A1 (en)	2016-07-29	2017-07-31	Fcrn antibodies and methods of use thereof

Publications (1)

Publication Number	Publication Date
DK3491025T3 true DK3491025T3 (da)	2024-01-15

Family

ID=61016731

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17835436.1T DK3491025T3 (da)	2016-07-29	2017-07-31	Fcrn-antistoffer og anvendelsesmetoder heraf

Country Status (22)

Country	Link
US (2)	US11345751B2 (da)
EP (2)	EP3491025B1 (da)
JP (3)	JP7094941B2 (da)
KR (3)	KR102717601B1 (da)
CN (2)	CN109790221B (da)
AU (1)	AU2017301915B2 (da)
BR (1)	BR112019001806A2 (da)
CA (1)	CA3032415A1 (da)
DK (1)	DK3491025T3 (da)
ES (1)	ES2968439T3 (da)
FI (1)	FI3491025T3 (da)
HR (1)	HRP20240048T1 (da)
HU (1)	HUE065780T2 (da)
IL (3)	IL320058A (da)
LT (1)	LT3491025T (da)
PL (1)	PL3491025T3 (da)
PT (1)	PT3491025T (da)
RS (1)	RS65070B1 (da)
SG (1)	SG11201900813RA (da)
SI (1)	SI3491025T1 (da)
SM (1)	SMT202400004T1 (da)
WO (1)	WO2018023136A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN118667010A (zh)	2015-01-30	2024-09-20	动量制药公司	Fcrn抗体及其使用方法
AU2017301915B2 (en) *	2016-07-29	2024-09-12	Momenta Pharmaceuticals, Inc.	FcRn antibodies and methods of use thereof
SG10202112298TA (en)	2017-05-11	2021-12-30	Nat Univ Singapore	Targeted prevention of maternal to foetal vertical transmission of infection
SG11202003944WA (en)	2017-12-08	2020-06-29	Argenx Bvba	Use of fcrn antagonists for treatment of generalized myasthenia gravis
WO2019118791A1 (en) *	2017-12-13	2019-06-20	Momenta Pharmaceuticals, Inc.	Fcrn antibodies and methods of use thereof
CN112153983B (zh)	2018-05-23	2024-09-13	杰克逊实验室	抗ngly-1抗体及使用方法
MA52790A (fr)	2018-06-08	2021-04-14	Argenx Bvba	Compositions et méthodes de traitement de la thrombopénie immune
SG11202100420UA (en) *	2018-07-20	2021-02-25	Momenta Pharmaceuticals Inc	Compositions of fcrn antibodies and methods of use thereof
US20210340251A1 (en) *	2018-07-20	2021-11-04	Momenta Pharmaceuticals, Inc.	Fcrn antibody compositions
EP3969125A4 (en) *	2019-05-17	2023-01-11	Alexion Pharmaceuticals, Inc.	USE OF ANTI-FCRN ANTIBODIES IN THE TREATMENT OF PEMPHIGHUS AND PEMPHIGOID DISEASES
AU2020319897A1 (en) *	2019-08-01	2022-02-24	Momenta Pharmaceuticals, Inc.	FcRn antibodies and methods of use thereof
KR20220100880A (ko) *	2019-11-19	2022-07-18	이뮤노반트 사이언시스 게엠베하	항-fcrn 항체를 이용한 온열 자가면역 용혈성 빈혈 치료 방법
WO2023030501A1 (zh) *	2021-09-03	2023-03-09	舒泰神（北京）生物制药股份有限公司	特异性识别FcRn的抗体及其应用
CN113912730B (zh) *	2021-12-14	2022-03-04	北京科诺信诚科技有限公司	缓释的抗FcRn抗体或抗原结合片段及其应用
EP4540283A1 (en)	2022-06-15	2025-04-23	argenx BV	Fcrn/hsa binding molecules and methods of use
AR131560A1 (es) *	2023-01-06	2025-04-09	argenx BV	Métodos para tratar pots mediante el uso de antagonistas de fcrn

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007501847A (ja)	2003-08-08	2007-02-01	ザリサーチファウンデイションオブステイトユニバーシティーオブニューヨーク	自己／同種免疫状態の治療用抗ＦｃＲｎ抗体
CN101124245A (zh)	2003-11-12	2008-02-13	比奥根艾迪克Ma公司	新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
EP1986690A4 (en)	2006-01-25	2009-05-13	Univ New York State Res Found	ANTIBODIES AGAINST FCRN FOR THE TREATMENT OF AUTO / ALLO IMMUNOIDES
WO2007104529A2 (en)	2006-03-13	2007-09-20	Ablynx N.V.	Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2009131702A2 (en) *	2008-04-25	2009-10-29	Dyax Corp.	Antibodies against fcrn and use thereof
CA2766065C (en)	2009-06-30	2020-07-21	Research Development Foundation	Immunoglobulin fc polypeptides
AU2012262007B2 (en)	2011-06-02	2017-06-22	Takeda Pharmaceutical Company Limited	Fc receptor binding proteins
GB201208370D0 (en) *	2012-05-14	2012-06-27	Ucb Pharma Sa	Antibodies
US20160108450A1 (en)	2013-05-02	2016-04-21	Momenta Pharmaceutcals, Inc.	Sialylated glycoproteins
KR101815265B1 (ko)	2013-06-20	2018-01-04	한올바이오파마주식회사	FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
DK3137504T5 (en) *	2014-04-30	2024-10-14	Hanall Biopharma Co Ltd	Antistofbinding til fcrn til behandling af autoimmunsygdomme
CN118667010A (zh)	2015-01-30	2024-09-20	动量制药公司	Fcrn抗体及其使用方法
HK1251483A1 (zh)	2015-05-12	2019-02-01	Synt免疫公司	人源化親和力成熟的抗fcrn抗體
AU2017301915B2 (en)	2016-07-29	2024-09-12	Momenta Pharmaceuticals, Inc.	FcRn antibodies and methods of use thereof

2017
- 2017-07-31 AU AU2017301915A patent/AU2017301915B2/en active Active
- 2017-07-31 WO PCT/US2017/044765 patent/WO2018023136A1/en active Application Filing
- 2017-07-31 SM SM20240004T patent/SMT202400004T1/it unknown
- 2017-07-31 DK DK17835436.1T patent/DK3491025T3/da active
- 2017-07-31 FI FIEP17835436.1T patent/FI3491025T3/fi active
- 2017-07-31 CN CN201780060620.6A patent/CN109790221B/zh active Active
- 2017-07-31 KR KR1020237006882A patent/KR102717601B1/ko active Active
- 2017-07-31 EP EP17835436.1A patent/EP3491025B1/en active Active
- 2017-07-31 IL IL320058A patent/IL320058A/en unknown
- 2017-07-31 KR KR1020247033727A patent/KR20240151878A/ko active Pending
- 2017-07-31 PL PL17835436.1T patent/PL3491025T3/pl unknown
- 2017-07-31 HR HRP20240048TT patent/HRP20240048T1/hr unknown
- 2017-07-31 ES ES17835436T patent/ES2968439T3/es active Active
- 2017-07-31 US US16/321,801 patent/US11345751B2/en active Active
- 2017-07-31 CA CA3032415A patent/CA3032415A1/en active Pending
- 2017-07-31 SI SI201731447T patent/SI3491025T1/sl unknown
- 2017-07-31 IL IL264528A patent/IL264528B2/en unknown
- 2017-07-31 CN CN202311567291.8A patent/CN117679506A/zh active Pending
- 2017-07-31 RS RS20240046A patent/RS65070B1/sr unknown
- 2017-07-31 KR KR1020197006049A patent/KR102505995B1/ko active Active
- 2017-07-31 IL IL302288A patent/IL302288B1/en unknown
- 2017-07-31 BR BR112019001806-9A patent/BR112019001806A2/pt unknown
- 2017-07-31 JP JP2019504902A patent/JP7094941B2/ja active Active
- 2017-07-31 SG SG11201900813RA patent/SG11201900813RA/en unknown
- 2017-07-31 PT PT178354361T patent/PT3491025T/pt unknown
- 2017-07-31 LT LTEPPCT/US2017/044765T patent/LT3491025T/lt unknown
- 2017-07-31 EP EP23195791.1A patent/EP4282487A3/en active Pending
- 2017-07-31 HU HUE17835436A patent/HUE065780T2/hu unknown
2022
- 2022-04-28 US US17/661,070 patent/US20230049725A1/en active Pending
- 2022-06-22 JP JP2022100315A patent/JP7442575B2/ja active Active
2024
- 2024-02-20 JP JP2024023875A patent/JP2024059765A/ja active Pending

Also Published As

Publication number	Publication date
IL264528A (da)	2019-03-31
JP2019526540A (ja)	2019-09-19
IL302288A (en)	2023-06-01
KR20240151878A (ko)	2024-10-18
EP4282487A2 (en)	2023-11-29
KR102505995B1 (ko)	2023-03-08
WO2018023136A1 (en)	2018-02-01
SG11201900813RA (en)	2019-02-27
PT3491025T (pt)	2024-01-18
HUE065780T2 (hu)	2024-06-28
IL320058A (en)	2025-06-01
EP3491025A1 (en)	2019-06-05
US20210238275A1 (en)	2021-08-05
IL302288B1 (en)	2025-05-01
CA3032415A1 (en)	2018-02-01
JP7094941B2 (ja)	2022-07-04
LT3491025T (lt)	2023-11-27
CN109790221B (zh)	2023-12-26
EP4282487A3 (en)	2024-02-14
EP3491025A4 (en)	2020-05-27
HRP20240048T1 (hr)	2024-03-29
AU2017301915B2 (en)	2024-09-12
PL3491025T3 (pl)	2024-03-25
KR102717601B1 (ko)	2024-10-16
IL264528B2 (en)	2023-09-01
SMT202400004T1 (it)	2024-03-13
KR20230035439A (ko)	2023-03-13
CN109790221A (zh)	2019-05-21
US20230049725A1 (en)	2023-02-16
FI3491025T3 (fi)	2024-01-12
EP3491025B1 (en)	2023-10-18
ES2968439T3 (es)	2024-05-09
RS65070B1 (sr)	2024-02-29
CN117679506A (zh)	2024-03-12
JP2022126783A (ja)	2022-08-30
JP2024059765A (ja)	2024-05-01
AU2017301915A1 (en)	2019-02-28
US11345751B2 (en)	2022-05-31
JP7442575B2 (ja)	2024-03-04
SI3491025T1 (sl)	2024-02-29
IL264528B1 (en)	2023-05-01
NZ750462A (en)	2024-04-26
KR20190037285A (ko)	2019-04-05
BR112019001806A2 (pt)	2019-05-07

Publication	Publication Date	Title
DK3618863T3 (da)	2023-08-21	Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3601358T5 (da)	2024-09-02	Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
IL264528B1 (en)	2023-05-01	Fcrn antibodies and methods of use thereof
DK3551660T3 (da)	2023-12-11	Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
DK3250610T3 (da)	2023-10-30	Fcrn-antistoffer og fremgangsmåder til anvendelse heraf
DK3353210T3 (da)	2025-01-06	Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3515478T3 (da)	2024-05-21	Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
DK3653221T3 (da)	2022-10-24	Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3356404T3 (da)	2021-10-25	Anti-pd1-antistoffer og fremgangsmåder til anvendelse
DK3303386T3 (da)	2024-10-28	Anti-Tau-antistoffer og fremgangsmåder til anvendlelse
DK3468990T3 (da)	2024-06-24	Anti-C5-antistoffer og anvendelser deraf
DK3215532T3 (da)	2020-01-02	Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3292149T3 (da)	2022-02-28	Aktiverbare anti-cd71-antistoffer og fremgangsmåder til anvendelse deraf
DK3436030T3 (da)	2022-11-21	Kimæriske receptorer og fremgangsmåder til anvendelse deraf
DK3148579T3 (da)	2021-03-08	Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
DK4063397T3 (da)	2024-07-22	Kimære antigenreceptorer baseret på enkelt-domæneantistoffer og fremgangsmåder til anvendelse deraf
DK3529257T3 (da)	2023-08-07	Oxysteroler og fremgangsmåder til anvendelse deraf
KR20180084817A (ko)	2018-07-25	항-siglec-9 항체 및 이의 이용 방법
DK3230319T3 (da)	2022-10-17	Anti-PD-1-antistoffer og fremgangsmåder til anvendelse deraf
DK3390442T5 (da)	2024-09-23	Anti-C5 antistoffer og fremgangsmåde til anvendelse deraf
DK3618928T5 (da)	2024-09-02	Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3126394T3 (da)	2020-01-13	Anti-OX40-antistoffer og fremgangsmåder til anvendelse
DK3280440T3 (da)	2023-02-20	Humaniserede anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
DK3565579T3 (da)	2023-09-04	Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
DK3368578T3 (da)	2021-05-25	Anti-HtrA1-antistoffer og fremgangsmåder til anvendelse deraf